Jazz Pharmaceuticals JAZZ Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's operating lease right-of-use assets in other assets?
- Jazz Pharmaceuticals (JAZZ) reported operating lease right-of-use assets in other assets of $55.8M in Q1 2026.
- How has Jazz Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Jazz Pharmaceuticals's operating lease right-of-use assets in other assets increased by 13.5% year-over-year, from $49.18M to $55.8M.
- What is the long-term trend for Jazz Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a -14.5% compound annual growth rate (CAGR), from $129.17M to $58.9M.